Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
- Eleni Gavriilaki*
- , Myriam Labopin
- , Ioanna Sakellari
- , Urpu Salmenniemi
- , Ibrahim Yakoub-Agha
- , Victoria Potter
- , Ana Berceanu
- , Alessandro Rambaldi
- , Inken Hilgendorf
- , Nicolaus Kröger
- , Stephan Mielke
- , Tsila Zuckerman
- , Jaime Sanz
- , Alessandro Busca
- , Hakan Ozdogu
- , Achilles Anagnostopoulos
- , Bipin Savani
- , Sebastian Giebel
- , Ali Bazarbachi
- , Alexandros Spyridonidis
*Corresponding author for this work
- George Papanikolaou General Hospital of Thessaloniki
- Sorbonne Université
- Helsinki University Hospital
- Lille University School of Medicine
- King's College Hospital
- Hôpital Jean Minjoz
- University of Milan
- Klinik f. Innere Medizin II
- University of Hamburg
- Karolinska Institutet
- Rambam Health Care Campus Israel
- Hospital Universitario La Fe
- Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
- Baskent University
- Vanderbilt University
- Maria Sklodowska-Curie Institute of Oncology
- American University of Beirut
- University of Patras
- Sheba Medical Center at Tel Hashomer
Research output: Contribution to journal › Article › peer-review
15
Scopus
citations